Total Payments
$26,132
2024 Payments
$142.29
Companies
13
Transactions
33
Medicare Patients
481
Medicare Billing
$108,962
Payment Breakdown by Category
Other$21,713 (83.1%)
Travel$2,338 (8.9%)
Food & Beverage$1,986 (7.6%)
Education$95.00 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,713 | 8 | 83.1% |
| Travel and Lodging | $2,338 | 3 | 8.9% |
| Food and Beverage | $1,986 | 21 | 7.6% |
| Education | $95.00 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $24,684 | 17 | $0 (2023) |
| Seattle Genetics, Inc. | $234.00 | 2 | $0 (2019) |
| BeiGene USA, Inc. | $218.85 | 3 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $162.57 | 2 | $0 (2023) |
| Janssen Biotech, Inc. | $126.92 | 1 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $124.90 | 1 | $0 (2019) |
| Genentech USA, Inc. | $116.86 | 1 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $100.72 | 1 | $0 (2017) |
| Amgen Inc. | $95.00 | 1 | $0 (2019) |
| Gilead Sciences, Inc. | $91.49 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142.29 | 2 | Gilead Sciences, Inc. ($91.49) |
| 2023 | $21,270 | 17 | Seagen Inc. ($20,889) |
| 2022 | $3,868 | 5 | Seagen Inc. ($3,795) |
| 2021 | $128.35 | 2 | Kite Pharma, Inc. ($82.61) |
| 2019 | $461.76 | 4 | Seattle Genetics, Inc. ($125.00) |
| 2018 | $160.90 | 2 | Seattle Genetics, Inc. ($109.00) |
| 2017 | $100.72 | 1 | Merck Sharp & Dohme Corporation ($100.72) |
All Payment Transactions
33 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $91.49 | General |
| 02/03/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $50.80 | General |
| Category: Oncology | ||||||
| 11/15/2023 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Oncology | ||||||
| 11/15/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $746.79 | General |
| Category: Oncology | ||||||
| 11/15/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $104.74 | General |
| Category: Oncology | ||||||
| 10/24/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $122.31 | General |
| Category: Oncology | ||||||
| 09/12/2023 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,462.50 | General |
| Category: Oncology | ||||||
| 06/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Oncology | ||||||
| 06/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $719.44 | General |
| Category: Oncology | ||||||
| 06/21/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $122.31 | General |
| Category: Oncology | ||||||
| 05/16/2023 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: Oncology | ||||||
| 05/16/2023 | Seagen Inc. | ADCETRIS (Biological) | Travel and Lodging | In-kind items and services | $871.78 | General |
| Category: Oncology | ||||||
| 05/16/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $116.31 | General |
| Category: Oncology | ||||||
| 03/15/2023 | E.R. Squibb & Sons, L.L.C. | ONUREG (Drug) | Food and Beverage | Cash or cash equivalent | $110.67 | General |
| Category: Oncology | ||||||
| 02/22/2023 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,135.00 | General |
| Category: Oncology | ||||||
| 02/22/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $119.93 | General |
| Category: Oncology | ||||||
| 02/17/2023 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $490.00 | General |
| Category: Oncology | ||||||
| 02/01/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $126.92 | General |
| Category: Oncology | ||||||
| 01/19/2023 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Monoclonal Antibody | ||||||
| 12/11/2022 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $72.57 | General |
| Category: Oncology | ||||||
| 12/10/2022 | Seagen Inc. | — | Food and Beverage | In-kind items and services | $73.39 | General |
| 11/30/2022 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,135.00 | General |
| Category: Oncology | ||||||
| 11/30/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $96.98 | General |
| Category: Oncology | ||||||
| 06/01/2022 | Seagen Inc. | ADCETRIS (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $490.00 | General |
| Category: Oncology | ||||||
| 12/11/2021 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $45.74 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 214 | 562 | $247,847 | $49,305 |
| 2022 | 6 | 165 | 392 | $174,201 | $32,221 |
| 2021 | 5 | 102 | 296 | $132,401 | $27,435 |
Total Patients
481
Total Services
1,250
Medicare Billing
$108,962
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 38 | 182 | $71,162 | $18,023 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 67 | 132 | $66,264 | $10,480 | 15.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 145 | $41,552 | $9,548 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 22 | 41 | $28,659 | $4,778 | 16.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 26 | 26 | $22,152 | $3,844 | 17.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 12 | $9,562 | $1,613 | 16.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 24 | $8,496 | $1,019 | 12.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 175 | $67,038 | $14,819 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 57 | 115 | $55,954 | $8,926 | 16.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 35 | 57 | $19,600 | $3,059 | 15.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 13 | 13 | $10,789 | $1,970 | 18.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 17 | 17 | $10,641 | $1,736 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 15 | $10,179 | $1,712 | 16.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 167 | $61,719 | $14,173 | 23.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 21 | 45 | $26,050 | $5,256 | 20.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 30 | 57 | $25,521 | $4,376 | 17.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $11,781 | $2,281 | 19.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $7,330 | $1,350 | 18.4% |
About Dr. Naseem Esteghamat, M.D
Dr. Naseem Esteghamat, M.D is a Hematology & Oncology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2013. The National Provider Identifier (NPI) number assigned to this provider is 1437491222.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Naseem Esteghamat, M.D has received a total of $26,132 in payments from pharmaceutical and medical device companies, with $142.29 received in 2024. These payments were reported across 33 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($21,713).
As a Medicare-enrolled provider, Esteghamat has provided services to 481 Medicare beneficiaries, totaling 1,250 services with total Medicare billing of $108,962. Data is available for 3 years (2021–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Sacramento, CA
- Active Since 03/20/2013
- Last Updated 11/23/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437491222
Products in Payments
- ADCETRIS (Biological) $24,845
- BRUKINSA (Drug) $218.85
- DARZALEX (Biological) $126.92
- Imbruvica (Drug) $124.90
- ONUREG (Drug) $110.67
- KEYTRUDA (Biological) $100.72
- Yescarta (Drug) $82.61
- IMBRUVICA (Drug) $72.57
- EMPLICITI (Biological) $51.90
- Poteligeo (Drug) $21.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Sacramento
Dr. Joseph Tuscano, M.d, M.D
Hematology & Oncology — Payments: $633,262
Hematology & Oncology $633,262
Adam Giermasz, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $518,605
Hematology & Oncology $518,605
Dr. David Gandara, M.d, M.D
Hematology & Oncology — Payments: $462,968
Hematology & Oncology $462,968
Dr. Scott Christensen, M.d, M.D
Hematology & Oncology — Payments: $391,606
Hematology & Oncology $391,606
Karen Kelly, M.d, M.D
Hematology & Oncology — Payments: $306,992
Hematology & Oncology $306,992
Paul Kaesberg, M.d, M.D
Hematology & Oncology — Payments: $221,939
Hematology & Oncology $221,939